Literature DB >> 2850409

[Effect of enalapril, furosemide and verapamil on cyclosporin concentration in whole blood].

C H Spes1, C E Angermann, M Anthuber, B M Kemkes, K Theisen.   

Abstract

Introduction of ciclosporin A into immunosuppressive therapy is considered a major progress in improving results of organ transplantation. Clinical use of ciclosporin, however, is limited by a low therapeutic index and toxic side effects. Therefore, interactions of ciclosporin with other drugs are clinically important. In our study, we used enalapril, furosemide and verapamil for treatment of arterial hypertension in cardiac transplant recipients and investigated the influence of these drugs on ciclosporin whole blood trough levels. The antihypertensive regimen used in this study normalized blood pressure in each of the 25 patients. Enalapril and furosemide did not influence ciclosporin levels. Adding verapamil, however, resulted in a significant increase of ciclosporin levels, whereas cessation of the drug in one patient treated with verapamil only lowered ciclosporin levels. Thus, when verapamil is introduced or discontinued in patients on ciclosporin, close monitoring of ciclosporin levels and dosage adjustment are necessary. Besides its specific effects verapamil allows reduction of ciclosporin dosage necessary to maintain unaltered levels, which is important regarding cost of therapy. In general, use of any drug with unknown influence on ciclosporin levels requires careful monitoring, even if information exists on other substances of the same group of drugs in this respect. This is especially indicated in drugs known to influence the hepatic cytochrome P450 enzyme system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850409     DOI: 10.1007/bf01727667

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  23 in total

1.  Economic impact of cyclosporine in transplantation.

Authors:  R W Evans; D L Manninen
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

2.  Cyclosporine A: a clinical evaluation of drug interactions.

Authors:  I Cockburn
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

Review 3.  Immunosuppressive therapy with cyclosporine for cardiac transplantation.

Authors:  B D Kahan
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

4.  Correlation between whole blood and plasma cyclosporine blood levels.

Authors:  K Uchida; A Orihara; Y Tominaga; N Yamada; N Nakanishi; M Kawai; T Kondo; T Akaza; K Morozumi; T Morimoto
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

5.  [Pharmacokinetics of cyclosporin A and the significance of blood levels for therapy].

Authors:  K Wonigeit
Journal:  Internist (Berl)       Date:  1985-09       Impact factor: 0.743

6.  [Side effects of cyclosporin following kidney transplantation and in patients with autoimmune diseases].

Authors:  B von Graffenried; P Krupp
Journal:  Internist (Berl)       Date:  1985-09       Impact factor: 0.743

7.  Effect of erythromycin on cyclosporine levels.

Authors:  R J Ptachcinski; B J Carpenter; G J Burckart; R Venkataramanan; J T Rosenthal
Journal:  N Engl J Med       Date:  1985-11-28       Impact factor: 91.245

8.  Cyclosporine-associated chronic nephropathy.

Authors:  B D Myers; J Ross; L Newton; J Luetscher; M Perlroth
Journal:  N Engl J Med       Date:  1984-09-13       Impact factor: 91.245

9.  Enhancement of high dose cyclosporin A toxicity by frusemide.

Authors:  P H Whiting; C Cunningham; A W Thomson; J G Simpson
Journal:  Biochem Pharmacol       Date:  1984-04-01       Impact factor: 5.858

10.  Nephrotoxicity of cyclosporine in spontaneously hypertensive rats: effects on blood pressure and vascular lesions.

Authors:  B Ryffel; H Siegl; R Petric; A M Muller; R Hauser; M J Mihatsch
Journal:  Clin Nephrol       Date:  1986       Impact factor: 0.975

View more
  3 in total

Review 1.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

2.  Sulfadiazine therapy for toxoplasmosis in heart transplant recipients decreases cyclosporine concentration.

Authors:  C H Spes; C E Angermann; H U Stempfle; K Wenke; K Theisen
Journal:  Clin Investig       Date:  1992-09

3.  Effects of graded exercise on blood pressure, heart rate, and plasma hormones in cardiac transplant recipients before and during antihypertensive therapy.

Authors:  C E Angermann; C H Spes; P Dominiak; J Weil; R Gerzer; H U Stempfle; B M Kemkes; K Theisen
Journal:  Clin Investig       Date:  1992-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.